Literature DB >> 8880291

Interaction between midazolam and clarithromycin: comparison with azithromycin.

R A Yeates1, H Laufen, T Zimmermann.   

Abstract

A comparative pharmacokinetic and pharmacodynamic investigation was carried out on the interaction between the hypnotic midazolam and 2 different macrolide-type antibiotics, clarithromycin and azithromycin. In an open randomized crossover study of 3 phases 12 healthy volunteers received either clarithromycin (250 mg twice a day for 5 days), azithromycin (500 mg once a day for 3 days) or no pretreatment. On the last day of antibiotic treatment they ingested 15 mg midazolam. Plasma samples were collected for midazolam analysis up to 24 h and pharmacodynamic performance measured by a series of tests up to 12 h. Pretreatment with clarithromycin caused large and statistically significant changes in both the pharmacokinetic and pharmacodynamic parameters of midazolam compared to control. For example, the AUC was increased from 248.84-888.75 hng/ml (factor of 3.57, p < 0.0001) and the mean duration of sleep increased from 135.4 min to 281.3 min (p < 0.05). No statistically significant effect was found with azithromycin in any test. It is concluded that a drug interaction exists between midazolam and clarithromycin which could be of clinical importance. No such effect is present with azithromycin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8880291

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  24 in total

Review 1.  Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin.

Authors:  J F Westphal
Journal:  Br J Clin Pharmacol       Date:  2000-10       Impact factor: 4.335

2.  Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide.

Authors:  Jari J Lilja; Mikko Niemi; Hanna Fredrikson; Pertti J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  2007-01-12       Impact factor: 4.335

Review 3.  Mini-series: II. clinical aspects. clinically relevant CYP450-mediated drug interactions in the ICU.

Authors:  Isabel Spriet; Wouter Meersseman; Jan de Hoon; Sandrina von Winckelmann; Alexander Wilmer; Ludo Willems
Journal:  Intensive Care Med       Date:  2009-01-09       Impact factor: 17.440

4.  Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate.

Authors:  Thomas M Polasek; John O Miners
Journal:  Eur J Clin Pharmacol       Date:  2006-01-17       Impact factor: 2.953

5.  Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin.

Authors:  Sara K Quinney; Xin Zhang; Aroonrut Lucksiri; J Christopher Gorski; Lang Li; Stephen D Hall
Journal:  Drug Metab Dispos       Date:  2009-11-02       Impact factor: 3.922

Review 6.  Macrolide antibiotics.

Authors:  R C Gordon
Journal:  Indian J Pediatr       Date:  1998 Jan-Feb       Impact factor: 1.967

Review 7.  Pharmacokinetic considerations in the eradication of Helicobacter pylori.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

8.  Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens.

Authors:  Daniel Moj; Nina Hanke; Hannah Britz; Sebastian Frechen; Tobias Kanacher; Thomas Wendl; Walter Emil Haefeli; Thorsten Lehr
Journal:  AAPS J       Date:  2016-11-07       Impact factor: 4.009

Review 9.  Clinical pharmacokinetics of clarithromycin.

Authors:  K A Rodvold
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

Review 10.  Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.

Authors:  David J Greenblatt; Jerold S Harmatz
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.